NKCFO LLC’s Amneal Pharmaceuticals AMRX Stock Holding History

NKCFO LLC’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-34,000	Closed	-$229K	–	106
2021 Q1	$229K	Buy	+34,000	New	+$188K	0.09%	65

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

NKCFO LLC's AMRX Position: Q2 2021 in Review

NKCFO LLC sold out of Amneal Pharmaceuticals (AMRX) in Q2 2021, closing a stake of 34,000 shares — an estimated $229K sold.

NKCFO LLC first reported a position in AMRX in Q1 2021 and held it in 1 quarter. The position peaked at $229K in Q1 2021. 160 funds tracked by Wall St. Rank hold AMRX as of Q2 2021.

NKCFO LLC reported no remaining Amneal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
NKCFO LLC sold 34,000 Amneal Pharmaceuticals shares in Q2 2021, an estimated $229K.
NKCFO LLC first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 1 quarter.
NKCFO LLC's Amneal Pharmaceuticals position peaked at $229K in Q1 2021.
160 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2021.

Based on NKCFO LLC's 13F filing for Q2 2021, filed 22 Jul 2021.